Company Overview and News

 
Eli Lilly, Amgen and More Big Pharma Earnings to Look For This Week

17h 247wallst
The health care sector has yet to see any significant earnings representation, but that will change this week. In fact, pharmaceutical and biotech investors are about to get a real earnings show, as this week will bring reports from some of the major players, in what is probably the busiest week this earnings season.
Upvote Downvote

 
Stocks To Watch: Earnings Blockbusters And Trump Talks Drug Prices

2018-04-21 seekingalpha
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning.
Upvote Downvote

 
U.S. IPO Weekly Recap: Pivotal Software Gains 5% As 5 IPOs Price And 3 Delay

2018-04-21 seekingalpha
• 8 IPOs had planned to raise $2.6 billion, but instead 5 IPOs raised $1.4 billion • The top-performer gained just 5%; the week averaged 2% • Despite tech sector's strength, Pivotal Software (PVTL) traded up just 3% • IPO market is not firing on all cylinders, but the week's deals had weaknesses • Tech sector to be tested next week with 4 tech IPOs, including DocuSign (DOCU) and Smartsheet (SMAR)
Upvote Downvote

 
Will the FDA Shoot Down Eli Lilly and Incyte Again?

2018-04-20 247wallst
Incyte Corp. (NASDAQ: INCY) and Eli Lilly and Co. (NYSE: LLY) will be under the microscope next week as the U.S. Food and Drug Administration (FDA) will decide the fate of their rheumatoid arthritis (RA) treatment.
Upvote Downvote

2
5 Drug Stocks Poised to Surpass on Earnings This Quarter

2018-04-17 investorplace
The first-quarter earnings season has just kicked off. Per the latest Earnings Preview, the bottom line of S&P 500 companies is expected to increase at a highly impressive rate of 16.6% on a year-over-year basis. This prospective upside marks the maximum quarterly earnings growth pace in seven years.
Upvote Downvote

 
2 Diabetes Growth Stocks And 1 Moonshot To Hold Through 2025

2018-04-17 seekingalpha
The two companies with the fastest growing projected diabetes revenues through 2022 are Eli Lilly and AstraZeneca.
Upvote Downvote

 
Johnson & Johnson: Recovering From A Deep Correction, Beats Earnings Estimates

2018-04-17 seekingalpha
The pharmaceutical giant has a long winning streak in terms of beating earnings estimates and this continued in the first quarter.
Upvote Downvote

2
This May Be The Best Time To Look At Incyte

2018-04-11 seekingalpha
Incyte (NASDAQ:INCY) has come under the spotlight and for all the wrong reasons. Last Friday saw the company releasing very disappointing results for its Keytruda-epacadostat combo therapy for advanced skin cancer, and that has pushed the stock down by a massive 23%, from $83.07 all the way down to $64.02. The failure of this combo has also cast a shadow of doubt on the future of all IDO1 inhibitors.
Upvote Downvote

1
The Major Pharma Stocks That Are Making Short Sellers Sick

2018-04-11 247wallst
Pharmaceutical companies usually are involved in a lengthy process of getting their drug candidates to market through clinical trials. There is a fair amount of risk involved, should a study come back negative or a candidate not be approved. Conversely, if a drug gains FDA approval or passes a clinical trial, there can be big upside.
Upvote Downvote

1
Week In Review: Concord Medical Raises $240 Million For China Radiology Services

2018-04-08 seekingalpha
Concord Medical Services (NYSE:CCM) announced that CICC Capital led an investment of between $238 million and $286 million in Concord's subsidiary Beijing Meizhong Jiahe Hospital Management (see story). The investors will hold 37.5% to 41.9% of Meizhong Jiahe's equity after the investment. Concord Medical Services Holdings Limited provides radiotherapy and diagnostic imaging services within public hospitals or in standalone medical centers, almost entirely in China.
Upvote Downvote

 
Your Daily Pharma Scoop: Major Setback For Incyte, Aclaris Agreement, MannKind Offering

2018-04-07 seekingalpha
Incyte (NASDAQ:INCY) shares tumbled more than 17% as investors digested the disappointing news with regard to the company’s phase 3 study evaluating the Epacadostat/Keytruda combination in patients with unresectable or metastatic melanoma.
Upvote Downvote

 
Venture Capital Deals Of The Week: Small Molecules And Software

2018-03-31 seekingalpha
Editor's note: Seeking Alpha is proud to welcome VCDeals as a new contributor. It's easy to become a Seeking Alpha contributor and earn money for your best investment ideas. Active contributors also get free access to the SA PRO archive. Click here to find out more »
Upvote Downvote

 
Which Major Pharma Stocks Short Sellers Are Keen On

2018-03-27 247wallst
Pharmaceutical companies usually are involved in a lengthy process of getting their drug candidates to market through clinical trials. There is a fair amount of risk involved, should a study come back negative or a candidate not be approved. Conversely, if a drug gains FDA approval or passes a clinical trial, there can be big upside.
Upvote Downvote

Related Articles

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

VSTM: Verastem Analysis and Research Report

2018-04-12 - Asif

Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...

CUSIP: 532457108